Seeking Alpha's Bullish Call on Eli Lilly Clashes with DeepValue's Risk-Focused 'Wait' Rating

What happened

A Seeking Alpha article published on March 12, 2026, rates Eli Lilly a strong buy with a $1,623 price target, citing near-term catalysts like the Q2 launch of oral GLP-1 orforglipron and Medicare access expansion. However, the DeepValue master report, based on recent SEC filings, maintains a 'WAIT' rating with a $1,050 base case, highlighting that LLY's current $1,018 stock price embeds optimistic assumptions. The report warns of no margin of safety due to high valuations—44.4x P/E and 35.8x EV/EBITDA—and risks from net-price pressure as GLP-1 drugs now represent 56% of revenue. Critical risks include potential government-mandated discounts, tolerability-driven discontinuations for orforglipron, and the need for early prescriptions to match Novo's benchmark of 26,109 weekly scripts. While the news article focuses on growth opportunities, the DeepValue analysis emphasizes that success hinges on unproven operational outcomes, making a cautious approach prudent.

Implication

The bullish news reinforces the crowded narrative around oral GLP-1 catalysts but ignores the pricing and persistence risks detailed in SEC filings, which could derail growth. DeepValue's analysis shows that LLY's valuation requires orforglipron to achieve at least 26,109 weekly prescriptions post-launch and avoid net-price erosion from Medicare expansion and competitive discounts. Without proof of these factors, the high multiples leave the stock vulnerable to a re-rating if government actions force material price step-downs by late 2026. Investors should monitor the April 2026 FDA decision, early prescription data, and any disclosures on pricing impacts over the next 3-6 months. A 'wait' strategy allows for confirmation of these milestones, reducing exposure to potential downside from the concentrated GLP-1 franchise.

Thesis delta

The Seeking Alpha article adds to bullish sentiment but does not change the core thesis from DeepValue, which remains that LLY's valuation is precarious without evidence of successful oral launch and stable net pricing. No new information mitigates the risks of government pricing actions or tolerability issues, so the delta is minimal, reinforcing the need for patience until operational data validates assumptions.